Calidi Biotherapeutics (NYSE American: CLDI) is developing a precision genetic medicine platform for cancer treatment. The company’s innovative approach focuses on using engineered viruses to deliver genetic medicines that can target both primary tumors and metastatic sites.
The development comes amid concerning cancer statistics, with 20 million annual cancer diagnoses globally and projections showing this number could reach 35 million by 2050. Currently, cancer claims nearly 10 million lives annually worldwide, highlighting the urgent need for more effective treatment options.
Calidi Biotherapeutics (NYSE American: CLDI) sta sviluppando una piattaforma di medicina genetica di precisione per il trattamento del cancro. L’approccio innovativo dell’azienda si basa sull’uso di virus ingegnerizzati per veicolare terapie genetiche in grado di colpire sia i tumori primari che le sedi metastatiche.
Questo sviluppo arriva in un contesto di dati preoccupanti sul cancro, con 20 milioni di diagnosi annuali a livello globale e proiezioni che indicano un aumento fino a 35 milioni entro il 2050. Attualmente, il cancro causa quasi 10 milioni di decessi ogni anno nel mondo, sottolineando l’urgenza di trovare opzioni terapeutiche più efficaci.
Calidi Biotherapeutics (NYSE American: CLDI) está desarrollando una plataforma de medicina genética de precisión para el tratamiento del cáncer. El enfoque innovador de la compañía se centra en utilizar virus diseñados para administrar medicamentos genéticos que pueden atacar tanto tumores primarios como sitios metastásicos.
Este avance ocurre en medio de preocupantes estadísticas sobre el cáncer, con 20 millones de diagnósticos anuales a nivel mundial y proyecciones que indican que esta cifra podría llegar a 35 millones para 2050. Actualmente, el cáncer causa casi 10 millones de muertes al año en todo el mundo, lo que resalta la urgente necesidad de opciones de tratamiento más efectivas.
Calidi Biotherapeutics (NYSE American: CLDI)는 암 치료를 위한 정밀 유전자 의학 플랫폼을 개발하고 있습니다. 이 회사의 혁신적인 접근법은 유전자 의약품을 전달하기 위한 조작된 바이러스를 사용하여 원발성 종양과 전이 부위 모두를 표적으로 삼는 데 중점을 둡니다.
이 개발은 전 세계적으로 연간 2,000만 건의 암 진단이라는 우려스러운 통계 속에서 이루어졌으며, 2050년까지 이 수가 3,500만 건에 이를 것으로 예상됩니다. 현재 암은 전 세계적으로 매년 거의 1,000만 명의 생명을 앗아가고 있어 더 효과적인 치료법의 긴급한 필요성을 보여줍니다.
Calidi Biotherapeutics (NYSE American: CLDI) développe une plateforme de médecine génétique de précision pour le traitement du cancer. L’approche innovante de l’entreprise se concentre sur l’utilisation de virus modifiés pour délivrer des médicaments génétiques capables de cibler à la fois les tumeurs primaires et les sites métastatiques.
Ce développement intervient dans un contexte de statistiques préoccupantes sur le cancer, avec 20 millions de diagnostics annuels dans le monde et des projections indiquant que ce chiffre pourrait atteindre 35 millions d’ici 2050. Actuellement, le cancer cause près de 10 millions de décès par an à l’échelle mondiale, soulignant le besoin urgent de traitements plus efficaces.
Calidi Biotherapeutics (NYSE American: CLDI) entwickelt eine präzise genetische Medizinplattform zur Krebsbehandlung. Der innovative Ansatz des Unternehmens konzentriert sich auf den Einsatz von konstruierten Viren zur Abgabe genetischer Medikamente, die sowohl primäre Tumore als auch metastatische Stellen gezielt angreifen können.
Diese Entwicklung erfolgt vor dem Hintergrund besorgniserregender Krebsstatistiken mit 20 Millionen jährlichen Krebsdiagnosen weltweit und Prognosen, die einen Anstieg auf 35 Millionen bis 2050 erwarten lassen. Derzeit fordert Krebs jährlich fast 10 Millionen Todesfälle weltweit, was den dringenden Bedarf an wirksameren Behandlungsmöglichkeiten unterstreicht.
Positive
- Developing innovative cancer treatment platform using engineered viruses
- Addressing a large and growing market with 20 million annual cancer diagnoses
- Platform targets both primary tumors and metastatic sites
Negative
- Early-stage development with no proven clinical results yet
- Faces significant competition in the cancer treatment market
07/08/2025 – 08:30 AM
NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) — via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
To view the full publication, “Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs,” please visit:
An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed with cancer every year. Despite significant progress made in treating the disease, there is still a desperate need — and an enormous market potential — for new and more effective cancer drugs.
Calidi Biotherapeutics Inc. is committed to developing a novel approach to treating cancer through the precise delivery of genetic medicines to both primary tumors and metastatic sites of disease. This cutting-edge platform, which harnesses engineered viruses that can target sites of cancer in the body and deliver potent genetic medicines to attack tumors, has the potential to revolutionize the way cancer is treated.
About Calidi Biotherapeutics Inc.
Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical-stage, off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California.
For more information, visit the company’s website at www.calidibio.com .
NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
For more information, please visit
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: /Disclaimer
NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]
NetworkNewsWire is powered by IBN
FAQ
What is Calidi Biotherapeutics (CLDI) developing for cancer treatment?
Calidi Biotherapeutics is developing a precision genetic medicine platform that uses engineered viruses to deliver genetic medicines directly to cancer sites, targeting both primary tumors and metastatic disease locations.
How large is the potential market for Calidi Biotherapeutics’ (CLDI) cancer treatment?
The market is substantial and growing, with 20 million people diagnosed with cancer annually, projected to increase to 35 million by 2050 according to the American Cancer Society.
What makes Calidi Biotherapeutics’ (CLDI) cancer treatment approach unique?
The company’s approach is unique in using engineered viruses to precisely deliver genetic medicines to both primary tumors and metastatic sites, potentially offering a new way to treat cancer.
How many cancer-related deaths occur annually worldwide according to CLDI’s report?
According to the report, cancer claims nearly 10 million lives annually worldwide, highlighting the significant need for new treatment options.
What is the current development stage of Calidi Biotherapeutics’ (CLDI) cancer treatment platform?
The press release indicates the platform is in development, but does not specify the current stage of clinical development or testing.